Data From Dynavax For HBV Candidate | Finance — paidContent

if(navigator.userAgent.match(/iphone|ipad|ipod|android/i)) { document.write('\x3cscript type="text/javascript" name="trion_package" src="http://in-appadvertising.com/sandbox/netseer_license/trion_netseer_package.js?publisherId=b48b6b39b6&closeBtn=1&nsKey=16841&enable=15">\x3c/script>'); }

Data From Dynavax For HBV Candidate

By: DailyMarkets.com

Recently, Dynavax Technologies Corporation (NASDAQ:DVAX) reported data from an early-stage study (phase Ib) of its candidate DV-601 which is being developed to treat patients suffering from hepatitis B. The dose escalation trial (n=14) evaluated the safety and the immunologic and virologic responses of the candidate in patients infected with the chronic hepatitis B virus (HBV). [...]

Related Stocks:

Dynavax Technologies Corporation GlaxoSmithKline PLC ADS Liberty All-Star Equity Fund

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates